HCPLive

AAD 2026 is shaping up to be a landmark meeting for dermatology — with first public phase 3 readouts for oral TYK2 inhibitors, a potential first-ever approved therapy for dermatomyositis, and more. Here's what to watch 👇 hcplive.com/view/aad-2026-…

Are TikTok skincare trends delaying patients from seeking real treatment? In this short video, Brittany Oliver, MD, highlights a growing issue dermatologists are seeing in clinic—and why it can lead to worse outcomes. 🎥Watch now. A collaboration between @DermTimesNow/ HCPLive

Review the clinical impact of updated international chronic spontaneous urticaria guidelines with Dr. Jason Hawkes and Dr. Nicole Chase. Watch here: hubs.li/Q047qxbj0 #CSU #Dermatology #Allergy

Are you attending #AAD2026?🤔 The upcoming dermatology conference will feature 2 late-breaking data sessions. We have prepared a preview of what's to come, highlighting key studies, the data of which is to be released during AAD... 🔗View the list: hcplive.com/view/aad-2026-…

ICYMI: SLIT uptake in the US remains limited by cost, coverage gaps, and adherence challenges, says Désirée Larenas-Linnemann, MD at #AAAAI26. Multi-allergen strategies show promise, but evidence is still evolving. View: hcplive.com/view/barriers-… #Allergy

Allergy experts weighed ruxolitinib, tapinarof, and roflumilast—new nonsteroidal creams that reshape #AtopicDermatitis care beyond steroids. Learn more now: hcplive.com/view/first-fla…

Corey Cavanaugh explains how he’s been making clinical choices surrounding the expanding therapeutic landscape for IgA nephropathy. Read more: hcplive.com/view/who-gets-…

ICYMI: The @US_FDA cleared MiniMed’s MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump designed to fit seamlessly into everyday life. Learn more: hcplive.com/view/fda-clear…

The @US_FDA just approved secukinumab for pediatric HS patients 12+ — the first new mechanism in nearly a decade.🔍 We spoke with trial investigator Alexa Kimball, MD, MPH, on what this means for younger patients. 🔗View: hcplive.com/view/reflectin…

Accelerated deep TMS delivered in 6 days matched standard multi-week outcomes in #TRD and led to faster remission (21 vs 28 days). Could shorter protocols improve access and adherence?🤔 Read more about the study here: hcplive.com/view/accelerat… #Depression

A new IL-17A inhibitor option for adolescents with hidradenitis suppurativa (HS) — trial investigator Alexa Kimball, MD, MPH, of @harvardmed breaks down the significance of the @US_FDA's latest approval of secukinumab. 🔗Learn more: hcplive.com/view/reflectin…

If you could choose the next destination for the #Aaaai Annual Meeting, where would it be? 🌎 We asked KOLs attending the meeting to share their picks. Watch their responses below. 🔗 For insights from the meeting, check out our full conference coverage: bit.ly/4bQSKl5

Evaluate IL-23 inhibitors in psoriasis care with Dr. Linda Stein Gold, Dr. Eingun James Song, and Dr. Jeffrey Crowley. Watch here: hubs.ly/Q047nDB20 #Psoriasis #Dermatology #IL23

🚨NEW🚨 The @US_FDA has approved icotrokinra for the treatment of psoriasis. The drug is specifically indicated for adults and pediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. 🔗hcplive.com/view/icotrokin…

ICYMI: The @US_FDA has issued a Complete Response Letter (CRL) to Aldeyra Therapeutics’ New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. View more: hcplive.com/view/fda-issue…

ICYMI: In a new #TheMedicalSisterhood podcast🎙️, Dr. Mona Shahriari speaks with Dr. Natasha Mesinkovska about visibility, mentorship, & carving your own path in medicine, in recognition of Women’s History Month. 🔗hcplive.com/view/the-medic… #WomensHistoryMonth #WomenInMedicine

KDIGO announced a formal update to the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). 🔗Read here: hcplive.com/view/kdigo-lau…

"We've been waiting for this for a long time." - Dr. Amy Paller of @NUFeinbergMed on why the ADorable-1 lebrikizumab data matters for young patients with moderate-to-severe #AtopicDermatitis. 🔗View: hcplive.com/view/significa…

SLIT uptake in the US remains limited by cost, coverage gaps, and adherence challenges, says Désirée Larenas-Linnemann, MD at #AAAAI26. Multi-allergen strategies show promise, but evidence is still evolving: hcplive.com/view/barriers-… #Allergy

New phase 3 data for lebrikizumab in #AtopicDermatitis down to 6 months of age — we spoke with investigator Amy Paller, MD @NUFeinbergMed on what the ADorable-1 findings mean for pediatric care. 🔗View her responses: hcplive.com/view/significa…